Starling Oncology, Inc. Finite-Lived Intangible Assets, Net
Starling Oncology, Inc. (DFPH) had Finite-Lived Intangible Assets, Net of $9.59 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Assets, Net $9.59M.
- 2026-03-31: Finite-Lived Intangible Assets, Net $10.30M.
- 2025-12-31: Finite-Lived Intangible Assets, Net $11.02M.
- 2025-09-30: Finite-Lived Intangible Assets, Net $11.73M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-06-30 | $9.59M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $10.30M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $11.02M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $11.73M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $12.45M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $14.04M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $14.81M 10-K · filed 2026-03-12 |
| 2024-09-30 | $15.58M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $16.36M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $17.13M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $17.90M 10-K · filed 2025-03-26 |
| 2023-09-30 | $18.56M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $19.34M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $17.23M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $17.96M 10-K · filed 2024-03-28 |
| 2022-09-30 | $18.66M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $19.38M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $17.57M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $18.25M 10-K · filed 2023-03-16 |
| 2020-12-31 | $19.52M 10-K · filed 2022-03-11 |